The Rise and Challenges of BioNTech: Beyond the COVID Vaccine Boom
BioNTech, based in Mainz, is shifting focus from COVID-19 vaccines to pioneering cancer treatments using mRNA technology. The company outperformed 2024 market expectations with an EPS of €1.08 and revenue…